SNPHY.US Santen Pharmaceutical Co

Healthcare Pharmaceuticals USA Stocks
12.81 USD
Close of Nov 17, 2026
9.80 13.77
Market cap
USD 4.12B
P/E
16.9x
P/B
2.14x
ROE
10.2%
Dividend yield
0.92%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is SNPHY.US undervalued?

Graham number
Price12.81
Graham value10.12
Premium26.6%

SNPHY.US trades 26.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Santen Pharmaceutical Co fundamental analysis

No fundamental analysis for Santen Pharmaceutical Co yet.

Santen Pharmaceutical Co stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocula…

Full company profile